Table 1.

Incidence of Baseline BCR-ABL Mutations

Patient Group	Patients Overall		Patients With Any Mutation
	No.	%	No.	%
All	281		114	41
Imatinib intolerant	89	32	9	10
Imatinib resistant	192	68	105	55
Primary resistance*	46	24	21	46
Secondary resistance†	146	76	84	58

^*Primary imatinib resistance was defined as no complete hematologic response at or after 3 months of therapy; as no minimal cytogenic response at or after 6 months; or as no major cytogenic response at or after 12 months.

^†Secondary imatinib resistance was defined as loss of complete hematologic response, loss of minimal cytogenic response, loss of major cytogenic response, or development of clonal evolution.